RxDoctor Payments Data

Joseph Mariglio, MD

Pulmonary Disease · Wyomissing, PANPI 1699795674

Payments from drug & device makers

$493in general payments, 2019–2025

Across 30 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$245
  • Genentech USA, Inc.$69
  • Sunovion Pharmaceuticals Inc.$46
  • Mylan Specialty L.p.$33
  • Teva Pharmaceuticals USA, Inc.$22
  • Inspire Medical Systems, Inc.$18
  • plus $61 from 4 others

What the payments were for

  • Food & beverage$493100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$493 in reported general payments places this provider in the 35th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$223,141
Medicare patients
662
Services billed
3,494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter304$244,398
GlassiaAlpha-1-Proteinase Inhibitor13$125,277
Breo ElliptaFluticasone/Vilanterol181$104,747
Breztri AerosphereBudesonide/Glycopyr/Formoterol46$34,520
Spiriva RespimatTiotropium Bromide51$31,311
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$25,063
Spiriva HandihalerTiotropium Bromide21$21,749
Fluticasone-SalmeterolFluticasone Propion/Salmeterol119$14,426
Albuterol Sulfate HfaAlbuterol Sulfate336$12,475
SymbicortBudesonide/Formoterol Fumarate31$11,290
Stiolto RespimatTiotropium Br/Olodaterol Hcl19$11,217
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate53$9,727
Arnuity ElliptaFluticasone Furoate21$8,150
Incruse ElliptaUmeclidinium Bromide17$7,710
Qvar RedihalerBeclomethasone Dipropionate14$5,333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$245$390,069550 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$22$5,33314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Wyomissing

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →